Obesity lab: India becomes ground zero for weight-loss drug race
This dual role is driven by an escalating obesity crisis within the country, coupled with the impending patent expirations of blockbuster weight loss medications and robust government incentives.
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Project Management
Technology
Others
others
CXO
Design Thinking
healthcare
Finance
Digital Marketing
Data Science
Data Analytics
PGDM
Cybersecurity
Leadership
Artificial Intelligence
Data Science
Operations Management
Degree
MBA
MCA
Product Management
Management
Healthcare
Public Policy
Skills you'll gain:
Portfolio Management
Project Planning & Risk Analysis
Strategic Project/Portfolio Selection
Adaptive & Agile Project Management
Duration:
6 Months
IIT Delhi
Certificate Programme in Project Management
Starts on
May 30, 2024
Get Details
Skills you'll gain:
Project Planning & Governance
Agile Software Development Practices
Project Management Tools & Software Techniques
Scrum Framework
Duration:
12 Weeks
Indian School of Business
Certificate Programme in IT Project Management
Starts on
Jun 20, 2024
Get Details
Global pharmaceutical giants like Novo Nordisk have recently launched Wegovy, intensifying competition with Eli Lilly's Mounjaro which debuted earlier this year, while Indian pharmaceutical companies such as Dr. Reddy's, Sun Pharma, Cipla, Biocon, and Lupin are actively developing their own generic versions, aiming for market entry as early as 2026 once key patents expire.
Innovator drugs enter the Indian market
Global pharmaceutical giants have recognised India's significant market potential, launching their advanced anti-obesity medications.
Eli Lilly & Co. launched its anti-obesity drug, Mounjaro (Tirzepatide), in India in March 2025. The company introduced the drug in a single-dose vial after receiving marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO).
Live Events
According to data compiled by Pharmarack, Mounjaro recorded sales of nearly ₹24 crore in its first three months (March–May). More recent data from ET indicates Mounjaro's usage doubled in June, with sales value growing by 18% to ₹50 crore for that month alone.
The Economic Times reported that a 2.5 mg vial of Mounjaro is priced at ₹3,500, and a 5 mg vial at ₹4,375, translating to ₹14,000–17,500 per month depending on weekly dose. A six-month treatment could cost about ₹1 lakh.
Sales of 2.5 mg injections rose to ₹5.08 crore in May from ₹4.80 crore in April and ₹1.42 crore in March, when it was launched, according to PharmaTrac data.
Danish firm Novo Nordisk also launched its anti-obesity drug, Wegovy (Semaglutide 2.4 mg), in major Indian cities on June 24. Originally planned for 2026, Novo Nordisk advanced Wegovy's launch to mid-2025 to directly challenge Mounjaro and capitalise on rising demand.
Wegovy is available in five dose strengths in India. The 0.25 mg, 0.5 mg, and 1 mg versions are priced at ₹4,336.25. The monthly cost would be ₹17,345, similar to Mounjaro. The 1.7 mg dose is priced at ₹24,280, and the 2.4 mg version at ₹26,015 for a month's supply.
India's growing middle and upper-middle classes can afford higher-cost treatments, making the country attractive to drug innovators. For example, Eli Lilly's Mounjaro, priced between ₹14,000–17,500 per month, has already seen significant uptake.
Novo Nordisk's oral semaglutide drug, Rybelsus, launched in January 2022, has grown from ₹26 crore to ₹412 crore, commanding a two-thirds share of the GLP-1 market.
Eli Lilly's tirzepatide-based Mounjaro, introduced in March 2025, clocked ₹50 crore in sales within its first quarter, capturing 8% of the market. Unit sales jumped from 11,637 in March to nearly 88,000 by June, nearly half of which were the 2.5 mg starter dose, indicating high patient onboarding and adherence.
Novo Nordisk's injectable Wegovy, launched in late June 2025, sold 1,788 units worth ₹2.53 crore across five dosage strengths, likely driven by patients previously using imported versions.
India's middle and upper-middle classes are now not just ablea to afford premium treatments: they're willing to. A once-unthinkable ₹15,000/month drug like Mounjaro is gaining real traction. That's not just a signal of rising income, it's a shift in mindset: people are prioritising preventive and lifestyle healthcare.
Novo Nordisk's Rybelsus growing 15x in two years shows this isn't a one-off. It's a trend. And with Mounjaro hitting ₹50 crore in just one quarter, the demand for GLP-1s, whether for diabetes or weight loss, is real and scaling fast.
High uptake of low starter doses also suggests something else: these aren't just prescriptions handed out to a few elite patients. Doctors are onboarding a lot of new users, and those users are sticking with the meds, at least through the early stages.
For the right kind of innovative drugs, especially in chronic lifestyle conditions, it's becoming a viable, profitable market even at global price points.
Generic tsunami looms as patents near expiry
The landscape of weight management drugs in India is poised for a significant shift with the impending patent expirations of Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications used for both type 2 diabetes and obesity.
Key patents for semaglutide, the active ingredient in Novo Nordisk's Ozempic and Wegovy, are set to expire around January 2026 in some regions and sometime next year in India. This "patent cliff" is a major catalyst for Indian generic manufacturers and Indian pharmaceutical companies are readying to bring in a range of generic versions of Novo Nordisk's semaglutide.
The move could open up cheaper access to weight-loss and diabetes drugs, possibly setting off a generics boom worth billions.
Novo Nordisk's semaglutide franchise generated $17 billion from Ozempic and $8.4 billion from Wegovy in 2024 alone, as per the company's 2024 annual financial results.
Patents for semaglutide are expected to lapse in over 100 countries, including Canada (January 2026), Brazil (March 2026), and India.
Indian pharma prepares to scale up
Now, major Indian players, including Dr. Reddy's, Biocon, Sun Pharma, Cipla, Lupin, and Aurobindo Pharma, are positioning themselves strategically.
Bengaluru-based OneSource Specialty Pharma is investing $100 million to scale up production, anticipating a revenue jump to $400 million within three years. Neeraj Sharma, CEO of OneSource, said in a media interview, 'Semaglutide will be a big part of it,' citing growing demand.
Dr. Reddy's CFO MV Narasimham stated that the company is ready for a "high-volume, low-cost" market and has end-to-end capabilities, as reported by Moneycontrol. Dr. Reddy's, which has been developing semaglutide for over a decade, is preparing for a global rollout, including injectable and oral formulations.
Biocon Chairperson Kiran Mazumdar-Shaw called the opportunity "very huge," noting the company's unique portfolio of GLP-1s and insulins. Biocon has already launched oral GLP-1 diabetes drug Liraglutide in the UK.
Biocon received CDSCO approval for its generic Liraglutide substance and product on June 2. It was also the first generic Liraglutide approved in the UK (March 2024), launched in February 2025, and approved in the EU (December 2024), demonstrating India's capability in complex peptide manufacturing.
Zydus Lifesciences is investing over ₹100 crore ($12 million) in a new manufacturing facility using proprietary technology to produce cost-effective semaglutide, as per Moneycontrol.
Hyderabad-based Divi's Laboratories, a key supplier of semaglutide components, has reported strong growth in its peptide business amid rising global demand, with HSBC projecting it to generate around $450 million in revenue from peptides by 2030.
Cipla signals intent to join the fray
Cipla, a major Indian drug firm, is actively preparing to enter the weight management segment in India. As reported by PTI on July 13, Umang Vohra, Cipla's MD and Global CEO, stated in the company's Annual Report for 2024-25, 'Obesity is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions.'
Cipla's consolidated revenue stood at ₹27,548 crore in FY25, with a net profit of ₹5,272 crore.
Government support and 'Make in India' for global export
The Indian government is actively supporting domestic pharmaceutical manufacturing through its Production-Linked Incentive (PLI) scheme. With an outlay of ₹1.97 lakh crore across 14 sectors, the scheme aims to boost the production of complex drugs, including Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients (APIs), as per the Press Information Bureau.
In 2024-25, the government disbursed ₹10,114 crore under the PLI schemes, with pharmaceutical drugs receiving ₹2,328 crore, as reported by ET.
Further, specific incentives for GLP-1 receptor agonists under the PLI framework are anticipated. Bloomberg reported on June 28 last year that Arunish Chawla, secretary with the Department of Pharmaceuticals, confirmed a PLI scheme for drugs used in the treatment of obesity and diabetes would be introduced in 2026. This aims to support domestic production of GLP-1 drugs.
This government backing, combined with patent expirations, is intended to position India not just as a domestic supplier but also as a major global exporter of affordable generic GLP-1s.
India's escalating obesity crisis
India is grappling with a rapidly increasing prevalence of overweight and obesity, impacting not just adults but children as well. According to the World Health Organization (WHO), almost half of all children under five who were overweight or living with obesity in 2024 resided in Asia — underscoring the regional impact.
India's status as the 'Diabetes Capital of the World,' with 77 million adults living with diabetes (WHO), runs parallel with the obesity epidemic.
A 2024 study published in the International Journal of Research and Review found that 29.7% of children aged 6–12 in Lucknow were overweight or obese, nearly three times the national average of 8.4%. This early trend of metabolic dysfunction provides a key 'laboratory' for studying disease progression and treatment responses.
Also Read:
Nearly 44 crore Indians will likely be obese by 2050: PM Modi sounds alarm over obesity report; calls it 'dangerous'
Market projections and challenges ahead
The global market for GLP-1-based weight loss drugs is projected to more than triple over the next six years, rising from $13.84 billion in 2024 to $48.84 billion by 2030, growing at a CAGR of 18.5%, according to Grand View Research.
India's growth trajectory is even sharper. The domestic GLP-1 receptor agonist market, valued at $110.55 million in 2024, is expected to grow at a 34.3% CAGR from 2025 to 2030 — nearly twice the global rate. This growth is driven by rising cases of type 2 diabetes and obesity, increased R&D, patent expiries, and the expected entry of generics.
According to the International Diabetes Federation's 2024 report, nearly 9 million Indian adults are currently at risk of diabetes. That figure could rise to 185 million by 2050, as projected by Grand View Research.
This rising disease burden is already reshaping India's pharmaceutical market. PharmaTrac data shows the anti-obesity drug market in India reached ₹628 crore as of June 2025, a fivefold increase over five years, driven by GLP-1 drugs like semaglutide and tirzepatide. With a 46% CAGR, this is now the fastest-growing therapeutic segment in the Indian pharma space. GLP-1s account for 75% of the market by value.
Despite booming demand, manufacturing GLP-1 drugs remains technically challenging. These peptide-based therapies require advanced facilities, significant investment, and specialised expertise. Delivery devices like injection pens add further complexity to the supply chain.
Legal battles are already unfolding. In May, Novo Nordisk sued Dr. Reddy's and OneSource Specialty in Delhi High Court, seeking to block domestic sales of their semaglutide generics. For now, Indian companies can continue to manufacture and export the drug.
Still, the global potential is massive. Goldman Sachs now estimates the anti-obesity drug market could hit $95 billion by 2030.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
22 minutes ago
- Time of India
GST's identity crisis: One nation, multiple headaches
Academy Empower your mind, elevate your skills Rajesh Sodhi still remembers the night of June 30, 2017. The Ludhiana-based textile manufacturer had stayed up past midnight, watching Parliament TV as the Goods and Services Tax (GST) was announced. 'One Nation, One Tax' was the clarion call. It sounded like music to his years on, Sodhi's enthusiasm has morphed into frustration. His factory now employs three accountants just to handle GST compliance . "We were promised simplicity," he says. "Instead, we got something more complicated than what we had before."Sodhi's story isn't unique. Across India, individuals and corporates alike are grappling with a tax framework that seems to have developed a mind of its complexity starts with the basics. Instead of 'One Tax', today's GST comes with five different tax rates: 0%, 5%, 12%, 18%, and 28%. Add in numerous exemptions, differential rates for services, and sector-specific rules, and you have a system that's making the old tax regime look something as basic as determining which rate applies to popcorn, which is still a hot-button issue months after the December 2024 GST Council meeting. Is it taxed at 5%, 12%, or 18%? The answer depends on factors so nuanced that even tax lawyers disagree, but the lowdown is: it's 5% if sold loose (such as in a movie theatre), 12% if packaged and savoury-flavoured, and 18% if caramelised. But if your popcorn comes bundled with your movie ticket, the GST would be 18% because this would be treated as a composite such as these have prompted entrepreneurs and companies, regardless of industry, to reclassify their products and services after routine audits, resulting in demands for additional tax ranging from lakhs to crores of rupees."There has to be a philosophy to taxation that informs decision-making. GST is far from the good and simple tax it was supposed to be," says former Finance Minister (FM) Yashwant Sinha. "When I was FM, I rationalised the multiple central excise rates down to three. GST has a rate multiplicity problem. It's creating classification, implementation, and filing issues. The slabs must be reduced— ideally to one."The digitalisation of the Indian economy has revealed another vital limitation in the implementation of GST. App-based services, digital payments, and e-commerce platforms have created a whole new category of tax disputes that the system wasn't designed to Karnataka, vendors are protesting after having received GST notices for UPI-based transactions exceeding ₹40 lakh a year. They are currently demanding that the state revoke such notices, and that enforcement of such rules be relaxed for small-scale consider fintech entrepreneurs whose lending platforms are embroiled in disputes over whether algorithmic credit scoring should be taxed as a software solution or a financial service, a distinction that could mean the difference between 0% and 18% tax rates. Software as a Service (SaaS) companies are unclear and thus unable to determine whether they're selling goods or services. There's confusion over e-commerce platforms' marketplace versus inventory models, and skill-based online gaming companies are still contending with the massive retrospective demands rising from the hike from 18% to 28%, on par with chance-based activities such as gambling and there's the 'luxury' classification. As Aarin Capital Chairman and former Infosys executive Mohandas Pai puts it:"Air conditioners and TVs larger than 32 inches are taxed at 28%, but these aren't luxury items. They're mass goods today. Two-wheelers and sedans are also not considered luxury goods in 2025. Cement, which is critical for building India, also falls in the 28% bracket. The number of slabs should be reduced, and classifications revised."A concern on GST's complexity is the volume of disputes it has generated. There were significant judgments pertaining to GST in 2024, rendered by High Courts across the nation. And 2025 is even busier, as evidenced by recent multinational corporations across sectors have taken the international arbitration route to seek relief from retrospective tax claims. Several disputes are ongoing. Two, online real money gaming platforms are challenging retrospective GST notices amounting to ₹1.12 lakh crore, which exceed the industry's turnover of approximately ₹20,000 crore. The Supreme Court heard their arguments on July 15 and has scheduled its final hearing for July 25. Three, food delivery aggregators are wondering whether delivery charges attract 5% or 18% GST, which could further dent make or break their razor-thin margins. Four, airlines and shipping companies were mired in compliance issues around 'place of supply rules' that confused rather than clarified. Lastly, life and health insurance companies contended with 18% GST, a move that was passed on to already-burdened cases highlight that retrospective tax actions, especially those related to indirect taxes like GST, may impact not only compliance but also business overall "pay first, argue later" approach is also a hurdle for micro, small, and medium enterprises (MSMEs), which have minimal resources, including cash flows, to sustain specialised tax compliance teams. And the paperwork doesn't help. This includes mandatory multi-factor authentication for GST portal access and restrictions on E-Way Bill (EWB) generation to curb fraudulent practices, which have added yet another layer of complexity to daily operations. As Rajesh Sodhi, the entrepreneur from Ludhiana, says:'Tax refund delays are my biggest problem. I'm spending most of my time on GST-related tasks. I became a businessman to sell hosiery and other textiles, not to become a tax expert. But that's what this system has forced me to become."Although India's foreign direct investment (FDI) performance has shown resilience, recent data indicates moderation in investment momentum. In FY25, net FDI inflows dropped to a record 96.5%, as reported by The Economic Times. This has everything to do with investors exiting lucrative IPOs here and Indian firms ramping up overseas investments. But here's something to consider: the retrospective application of tax laws also undermines the principle of legal certainty, which is critical for investor confidence. Such enforcement imposes additional due diligence requirements and risk assessment protocols on foreign investors, particularly in sectors with complex supply chains and cross-border Financial Times reported that disputed tax demands, totalling around ₹13.4 lakh crore (as of March 2024), may have contributed to the decrease in net FDI inflows. Automaker Volkswagen is contesting a tax demand of approximately ₹12,000 crore related to import duties stemming from a 12-year investigation. Similarly, Maruti Suzuki (~₹20,000 crore) and Hyundai (~₹4,000 crore) are also among the top companies. Such prolonged battles and uncertainty surrounding tax obligations could raise concerns among investors about the predictability of India's tax are signs that policymakers are finally acknowledging pain points. Owing to Budget 2025, enterprises can expect some GST rate rationalisation in the 56th GST Council meeting, to be held later this month. Two major measures reportedly being considered are the elimination of the 12% slab and the abolition of GST altogether for term for businesses like Sodhi's, the question isn't whether reforms will come. It's whether they'll arrive soon enough. After eight years of promises and patches, India's entrepreneurs are running out of patience with the great tax answer, it seems, is written in the stars… or perhaps in the next GST Council meeting.
Time of India
22 minutes ago
- Time of India
Hamas Vindicated? Explosive Report Junks Trump Admin's Gaza Aid Loot Claim: ‘Israel Not Weaponising'
'Looking For High-Scoring Partnership': Modi Bats For Youth, Farmers, MSMEs & Global Trade | UK FTA India and the United Kingdom have signed a historic Free Trade Agreement (FTA) that promises to double bilateral trade, unlock new markets for Indian exports, and make UK products more affordable in India. Signed by Commerce Minister Piyush Goyal and UK counterpart Jonathan Reynolds, the deal was sealed in the presence of PM Modi and UK PM Keir Starmer. Modi called the moment 'historic,' comparing India-UK ties to a cricket match played with a straight bat. From Indian textiles and engineering goods to UK whisky and medical devices, the FTA aims to benefit both nations, but especially India's youth, farmers, fishermen, and MSMEs. This deal puts India on a stronger global footing, showing that even amid turbulent global trade dynamics, Delhi is batting with vision, confidence, and purpose. Watch how India's 'Vision 2035' is turning trade into transformation.#pmmodi #narendramodi #indiaukdeal #modistarmer #modiukvisit #modistarmermeeting #modicrickettalk #cricket #modicricketanalogy #cricketanalogy #fta #indiauktarde #freetradeagreement #brexitindia #globaltrade #newchapter #indiaeconomy #ukindiarelations #modidiplomacy #keirstarmer #toi #toibharat #bharat #trending #breakingnews #indianews #toi #toibharat #bharat #trending #breakingnews #indianews 33.7K views | 22 hours ago
Time of India
22 minutes ago
- Time of India
Indian automobile industry may grow by 6-7% in FY26 amid damp consumer demand: Report
The Indian automobile sector is expected to grow by 6-7 per cent in the fiscal year (FY26) amid damp consumer demand across most vehicle categories, according to a report by Motilal Oswal. As per the report, volumes in the two-wheeler category fell the highest compared to passenger vehicles (PV) and commercial vehicles (CVs) in the first quarter of FY26 (Q1FY26). The two-wheeler segment remained under pressure due to muted demand. In the April-June quarter of FY26, motorcycle sales fell by 9 per cent year-on-year, ICE scooter sales declined 5 per cent year-on-year, and moped volumes also slid by 11 per cent year-on-year. By contrast, the PV category posted a 1.4 per cent decline in volumes, with the small car segment being impacted significantly due to the volumes of key models such as Maruti Alto, Spresso, and Celerio witnessing sharp year-on-year declines in Q1FY26. The commercial vehicle (CV) segment, meanwhile, saw a marginal decline in volumes. While MHCV goods registered a 4.5 per cent dip, LCV goods fell by 0.5 per cent. However, bus sales remained a bright spot, with MHCV buses growing 7.6 per cent and LCV buses up 8.8 per cent. In terms of OEMs' performance, Tata Motors underperformed across all four CV sub-segments, while VE Commercial Vehicles (VECV) managed to outperform in most, according to Motilal Oswal. 'Our focus would be to deliver industry-beating growth (in FY26) because one, this year is possibly the strongest product cycle for us, and the freshest portfolio. We have a low base for FY25. On the SUV side also, we will be coming with a multipowertrain on Harrier and Safari, including the petrol version,' said Shailesh Chandra, MD, Tata Motors & Tata Passenger Electric Mobility, earlier at the Q4FY25 post-earnings conference call in May. Chandra had said that there would be re-varianting and repositioning of certain products in the portfolio. 'We have the full year for Nexon CNG and also, we will launch Sierra. So, even SUVs are going to be strong…it's going to be a very strong year for us,' he said. The top Tata Motors executive had said that the company will strengthen its value proposition of its existing EV products, in terms of value-price equation. 'It's going to be a strong year for us on the EV side also,' Chandra said. Its homegrown rival, Mahindra & Mahindra, too, is confident of growth this year. Nalinikant Gollagunta, CEO (automotive division) at Mahindra & Mahindra, said the company remains confident of mid-to-high teens growth in the SUV segment, along with strong double-digit export growth. He also reaffirmed guidance for high single-digit growth in LCVs for the full fiscal, according to a report by news agency ANI . The brokerage said that the industry may remain in a cautious phase in the near term, with a rebound largely dependent on rural demand recovery, fuel price stability, and broader economic conditions.
